Whalesbook
Metropolis Healthcare Ltd. has delivered a robust financial performance, signaling strong momentum in the diagnostic services sector. The company’s ability to more than double its net profit in the fourth quarter is a testament to its operational strengths and strategic market positioning.
Margin Expansion Drivers
The substantial improvement in profitability was primarily driven by enhanced operational efficiencies and strategic pricing initiatives. EBITDA surged by 73.4% year-on-year, reaching ₹108 crore, a significant jump from ₹62.3 crore. This operational leverage allowed margins to expand by 7.4 percentage points to 25.4%, up from 18% in the same period last year. Revenue per patient (RPP) and revenue per test (RPT) also saw healthy increases of 11% and 8% respectively, indicating better yield from services and higher consumer adoption of premium diagnostic tests.
Segment Performance
Both Business-to-Consumer (B2C) and Business-to-Business (B2B) segments contributed to the top-line growth. B2C revenues rose 20%, boosted by increased demand for preventive and specialized testing, alongside effective hyperlocal marketing and digital engagement strategies. The B2B segment performed even stronger, with revenues climbing 28%, attributed to client retention, successful hospital outsourcing partnerships, and improved service reliability. The company’s specialized offerings, including the TruHealth portfolio (up 24%) and the broader specialty portfolio (up 31%), reflect a growing consumer preference for advanced and proactive healthcare solutions.
Industry Outlook and Company Strategy
Ameera Shah, Promoter and Executive Chairperson, highlighted the evolving diagnostics industry in India, characterized by a shift towards organized, science-led platforms emphasizing trust and accuracy. She stated that Metropolis's focus on scientific excellence and strong clinician relationships positions it favorably within this dynamic healthcare landscape. The expansion of its network beyond 5,000 centers across India underscores its commitment to accessibility and market penetration, further solidifying its competitive standing.
Dividend and Network Growth
Reflecting its strong financial health and commitment to shareholder returns, Metropolis Healthcare announced a second interim dividend of ₹1 per equity share for FY2025-26. The company fixed May 19, 2026, as the record date for this payout, to be disbursed within 30 days. This dividend declaration follows a period of significant network expansion, crossing the 5,000-center milestone, which enhances its geographical reach and service delivery capabilities across the country.
Stock Performance
On the day of the results announcement, May 13, shares of Metropolis Healthcare Ltd. closed at ₹550 on the BSE, marking a marginal increase of 0.36%, or ₹2, from the previous close. This modest gain suggests that while the results were positive, the market had perhaps already priced in some of this optimism, or broader market sentiment influenced the immediate stock movement.